Investigation of the temporal distribution of anti-VEGF drugs in the retina and the correlation with the distribution of FcR isoforms

Jianzhong He, Y. Jiang, Ruixue Yang, Ziwen Lu, Zhihuan Li, Zhigang TuGenes 2025 · DOI

TL;DR

This study investigates how different anti-VEGF drugs distribute within the rat retina over time, revealing that drugs without Fc fragments (brolucizumab, ranibizumab) penetrate deeper and faster than those with Fc fragments (bevacizumab). This difference is linked to the expression of Fc receptors in the retina, suggesting Fc-fragment-containing drugs may have altered pharmacokinetics due to FcR binding.

What Problem Does This Paper Address?

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema are significant causes of vision loss, often driven by elevated vascular endothelial growth factor (VEGF). Anti-VEGF therapies are the cornerstone of treatment, but these drugs vary in their molecular structure, specifically the presence or absence of an Fc fragment. This structural difference is hypothesized to influence how these drugs distribute within the complex layers of the retina, impacting their therapeutic efficacy and onset of action. While it's known that Fc fragments can interact with Fc receptors (FcRs) present in ocular tissues, there's a notable gap in understanding the precise temporal distribution of different anti-VEGF drugs within the retina and how this relates to the distribution of FcR isoforms. This paper aims to fill that gap by characterizing the penetration dynamics of Fc-containing and Fc-free anti-VEGF drugs in normal and AMD-model rat retinas and correlating it with FcR expression.

Methods

The researchers employed a multi-pronged approach:

  • Intravitreal Injections: Brolucizumab, ranibizumab, and bevacizumab were injected directly into the vitreous humor of normal rat eyes.
  • ELISA Assays: These were used to quantify the concentration of each drug in different retinal layers over time (up to 72 hours post-injection).
  • Immunohistochemistry (IHC): This technique was used to visualize the spatial distribution of the drugs within the retinal layers and to map the expression of Fc receptor (FcR) isoforms (FcRn, FcyRI, FcyRII, FcyRIII).
  • 3D Computational Models: These models were used to visualize the drug and FcR distribution across the defined Inner, Outer, and Deep retinal layers.
  • Fluorescence In Situ Hybridization (FISH): This method was used to examine the mRNA distribution of FcRn and FcyRI.
  • AMD Models: The drug distribution studies were also conducted in rat eyes modeled to mimic AMD to assess the impact of disease-related structural changes.

Datasets

The study utilized normal rat eyes and rat eyes with experimentally induced AMD models. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Fc Fragment Matters for Penetration: The presence of an Fc fragment significantly impacts how quickly and deeply an anti-VEGF drug can penetrate the retina. Drugs without Fc fragments (brolucizumab, ranibizumab) showed much faster and more extensive penetration into deeper retinal layers compared to bevacizumab, which has an Fc fragment.
  • Fc Receptors as Potential "Brakes": Fc receptors (FcRs) are expressed throughout the rat retina, with FcRn and FcyRI being the most abundant isoforms. The binding of Fc-containing drugs to these receptors likely influences their distribution and retention within the retina, potentially slowing their diffusion into deeper layers.
  • AMD Alters Drug Dynamics: In AMD-model retinas, the structural changes associated with the disease appear to increase retinal permeability, allowing for more accelerated entry of bevacizumab into the Outer and Deep layers compared to healthy retinas. However, even in AMD models, brolucizumab and ranibizumab still demonstrated faster penetration into the Deep layer within the first 24 hours.
  • Size vs. Fc Interaction: The findings suggest a dual mechanism for drug distribution: passive diffusion influenced by drug size (larger drugs like bevacizumab are hindered) and active transport/retention mediated by FcR binding for Fc-containing drugs.

Key Results

  • Rapid Initial Penetration: All three drugs (brolucizumab, ranibizumab, bevacizumab) rapidly penetrated the vitreous and reached peak concentrations in the Inner retinal layer within 6 hours post-injection in normal rats.
  • Differential Deep Layer Penetration: At 24 hours post-injection in normal rats, brolucizumab showed 70% penetration in the Outer layer, while bevacizumab only reached 45%. In the Deep layer, brolucizumab and ranibizumab levels were significantly higher than bevacizumab at 24, 48, and 72 hours.
  • FcR Expression: FcRn and FcyRI were identified as the major FcR isoforms in normal rat retinas, with higher protein and mRNA expression in the Deep and Outer layers compared to the Inner layer.
  • AMD Impact: In AMD models, bevacizumab's penetration into the Outer and Deep layers was enhanced by 48-72 hours compared to normal retinas, but brolucizumab and ranibizumab still showed faster penetration into the Deep layer at 24 hours.

Limitations and Future Work

  • Animal Model: The study was conducted in rat models, and direct translation to human physiology requires further investigation.
  • FcR Isoform Specificity: While FcRs were mapped, the precise binding affinities and functional roles of each isoform in mediating drug transport for each specific drug were not fully elucidated.
  • Clinical Relevance: While the findings align with observed clinical responses (e.g., rapid action of ranibizumab), further clinical studies are needed to confirm these distribution patterns in human patients.

The authors suggest that these findings provide a better understanding of anti-VEGF drug pharmacokinetics and could inform the development of novel ophthalmic medications with optimized delivery profiles. The differential penetration observed highlights the potential for brolucizumab and ranibizumab to be superior options for treating conditions involving deep retinal or choroidal edema.

Summary updated

BibTeX
@inproceedings{he2025investigation,
  author = {Jianzhong He and Y. Jiang and Ruixue Yang and Ziwen Lu and Zhihuan Li and Zhigang Tu},
  title = {{Investigation of the temporal distribution of anti-VEGF drugs in the retina and the correlation with the distribution of FcR isoforms}},
  booktitle = {Genes},
  year = {2025},
  doi = {10.1016/j.gendis.2025.101698},
}
Figure